This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) A purified variant B7-H1 polypeptide which~~, wherein said variant polypeptide~~ is a variant of a wild-type B7-H1polypeptide ~~that binds to PD-1~~, wherein said wild-type B7-H1 polypeptide binds to PD-1 and has the amino acid sequence set forth in SEQ ID NO:4, wherein said variant B7-H1 polypeptide comprises a substitution of the amino acid at position 67, 126, 37, 115, 124, 31, 49, 62, 98, or 129 of SEQ ID NO:4[[~~,~~]] and ~~wherein said variant B7-H1 polypeptide~~ has binding affinity for PD-1 that is detectable by ELISA but is reduced by at least 50 percent as compared to the binding affinity of said wild-type B7H1 polypeptide for PD-1.

Claim 2. (Cancelled)

Claim 3. (Cancelled)

Claim 4. (Cancelled)

Claim 5. (Previously Presented) The purified variant B7-H1 polypeptide of claim 1, comprising a substitution of the amino acid at position 67 of SEQ ID NO:4.

Claim 6. (Previously Presented) The purified variant B7-H1 polypeptide of claim 5, wherein said substitution comprises replacing the amino acid at position 67 of SEQ ID NO:4 with an alanine residue.

Claim 7. (Previously Presented) The purified variant B7-H1 polypeptide of claim 1, comprising a substitution of the amino acid at position 126 of SEQ ID NO:4.

Claim 8. (Previously Presented) The purified variant B7-H1 polypeptide of claim 7, wherein said substitution comprises replacing the amino acid at position 126 of SEQ ID NO:4 with an alanine residue.

Claim 9. (Previously Presented) The purified variant B7-H1 polypeptide of claim 1, comprising a substitution of the amino acid at position 37 of SEQ ID NO:4.

Claim 10. (Previously Presented) The purified variant B7-Hl polypeptide of claim 9, wherein said substitution comprises replacing the amino acid at position 37 of SEQ ID NO:4 with a tyrosine residue.

Claim 11. (Previously Presented) The purified variant B7-H1 polypeptide of claim 1, comprising a substitution of the amino acid at position 115 of SEQ ID NO:4.

Claim 12. (Previously Presented) The purified variant B7-H1 polypeptide of claim 11, wherein said substitution comprises replacing the amino acid at position 115 of SEQ ID NO:4 with an alanine residue.

Claim 13. (Previously Presented) The purified variant B7-H1 polypeptide of claim 1, comprising a substitution of the amino acid at position 124 of SEQ ID NO:4.

Claim 14. (Previously Presented) The purified variant B7-H1 polypeptide of claim 13, wherein said substitution comprises replacing the amino acid at position 124 of SEQ ID NO:4 with a serine residue.

Claims 15–41. (Cancelled)

Claim 42. (Currently Amended) A polypeptide fragment of murine B7-H1 (SEQ ID NO:4)~~,~~ ~~wherein said polypeptide fragment~~ which comprises a variant at position 69 or 113 with respect to the sequence set forth in SEQ ID NO:4~~, wherein said polypeptide fragment~~ and which inhibits binding of murine B7-H1 to murine PD-1, ~~and wherein~~ said polypeptide fragment ~~is about~~ comprising 259 to ~~about~~ 271 ~~amino acids in length, and~~ amino acid residues and having ~~wherein the amino acid at position~~ Thr-290 of SEQ ID NO:4 ~~is~~ at the carboxy terminal end ~~of said polypeptide fragment~~.

Claim 43. (Cancelled)

Claim 44. (Withdrawn) A method of inhibiting the interaction between PD-1 and B7-H1, said method comprising contacting a PD-1 polypeptide with the polypeptide fragment of claim 42.

Claim 45. (Withdrawn) The method of claim 44, wherein said PD-1 is in vitro.

Claim 46. (Withdrawn) The method of claim 44, wherein said PD-1 is in a mammal.

Claim 47. (Withdrawn) The method of claim 46, wherein said method comprises administering the polypeptide fragment to the mammal.

Claim 48. (Withdrawn) The method of claim 46, wherein said method comprises administering a nucleic acid encoding said polypeptide fragment to said mammal.

Claim 49. (Withdrawn) The method of claim 48, wherein said method comprises administering a cell transfected or transduced with said nucleic acid to said mammal, wherein said cell is a cell, or a progeny of a cell, that prior to said transfection or said transduction, was obtained from said mammal.

Claim 50. (Withdrawn) The method of claim 46, wherein said mammal is a human.

Claims 51–60. (Cancelled)

Claim 61. (Previously Presented) The purified variant B7-H1 polypeptide of claim 1, comprising a substitution of the amino acid at position 31 of SEQ ID NO:4.

Claim 62. (Previously Presented) The purified variant B7-H1 polypeptide of claim 61, wherein said substitution comprises replacing the amino acid at position 31 of SEQ ID NO:4 with a serine residue.

Claim 63. (Previously Presented) The purified variant B7-H1 polypeptide of claim 1, comprising a substitution of the amino acid at position 49 of SEQ ID NO:4.

Claim 64. (Previously Presented) The purified variant B7-H1 polypeptide of claim 63, wherein said substitution comprises replacing the amino acid at position 49 of SEQ ID NO:4 with a serine residue.

Claim 65. (Previously Presented) The purified variant B7-H1 polypeptide of claim 1, comprising a substitution of the amino acid at position 62 of SEQ ID NO:4.

Claim 66. (Previously Presented) The purified variant B7-Hl polypeptide of claim 66, wherein said substitution comprises replacing the amino acid at position 62 of SEQ ID NO:4 with a serine residue.

Claim 67. (Previously Presented) The purified variant B7-Hl polypeptide of claim 1, comprising a substitution of the amino acid at position 98 of SEQ ID NO:4.

Claim 68. (Previously Presented) The purifed variant B7-H1 polypeptide of claim 67, wherein said substitution comprises replacing the amino acid at position 98 of SEQ ID NO:4 with a phenylalanine residue.

Claim 69. (Previously Presented) The purified variant B7-H1 polypeptide of claim 1, comprising a substitution of the amino acid at position 129 of SEQ ID NO:4.

Claim 70. (Previously Presented) The purified variant B7-H1 polypeptide of claim 69, wherein said substitution comprises replacing the amino acid at position 129 of SEQ ID NO:4 with a serine residue.